Background : Specific data on anti-H. pylori treatments in elderly people are very scarce. The aim of the study was to evaluate in the elderly the efficacy of different anti-H. pylori therapies and the behaviour of serum anti-H. pylori antibodies, pepsinogen A and C, and PGA\PGC ratio induced by the anti-H. pylori treatment. 
INTRODUCTION

The prevalence of Helicobacter pylori infection is known to
Correspondence to : Dr A. Pilotto antibodies, pepsinogen A and C, and PGA\PGC ratio were measured. Results : Ten patients (8.2 %) dropped out of the study. Six patients (4.9 %) reported side-effects. The eradication rates of the six regimens, expressed using intention-to-treat and per protocol analysis, were, respectively : (A) 39 % and 44 % ; (B) 50 % and 56 % ; (C) 65 % and 77 % ; (D) 47 % and 50 % ; (E) 85 % and 90 % ; and (F) 83 % and 87 %. The triple therapy for regimens E and F was significantly more effective than dual therapies (regimens A and D ; intention-to-treat l P 0.007, per protocol l P 0.001) or the triple therapy for regimens B and C (intention-to-treat l P 0.009, per protocol l P 0.03). Patients cured of H. pylori infection showed a significant decrease in the activity of gastritis (P 0.0001), a significant drop in IgG anti-H. pylori (P l 0.0004) and pepsinogen C (P 0.0001), and an increase in PGA\PGC ratio (P 0.001), while patients remaining H. pyloripositive showed no changes in the serum parameters. Conclusions : In the elderly, triple therapy with omeprazole jmetronidazolejclarithromycin for 1 week is well tolerated and highly effective ; anti-H. pylori antibody and PGC serum levels decrease soon after anti-H. pylori therapy only in patients cured of H. pylori infection.
increase with age, in countries with low and high socioeconomic conditions ;" -$ furthermore, it has been reported that upper gastrointestinal tract lesions, and particularly gastric ulcer and chronic gastritis, increase with age in dyspeptic patients.% However, specific data on # 1996 Blackwell Science Ltd anti-H. pylori treatments in elderly people are somewhat rare. This fact is even more enhanced if we consider that elderly patients may present more problems than younger people regarding the dosage of drugs, sideeffects and compliance.& Elimination of H. pylori from the gastric mucosa induces an improvement in histological gastritis activity' and modifications in some serum parameters, such as specific anti-H. pylori antibodies( ,) and pepsinogens A and C,* ,"! were reported to occur some months after the cure. However, until now few data have been published about elderly people"" and there are conflicting opinions at present regarding the clinical usefulness of such serum parameters in the elderly. The aims of this study were, therefore : (1) to evaluate the tolerance and efficacy, including both the eradication of H. pylori and the improvement in histological evidence of gastritis, of different anti-H. pylori treatments in elderly patients ; and (2) to study the modifications induced by the cure of H. pylori infection in serum anti-H. pylori antibodies, pepsinogens A (PGA) and C (PGC).
MATERIALS AND METHODS
Patients and treatments
The study involved 121 elderly dyspeptic patients (60 males and 61 females, mean age 73 years, range 61-89 years) affected by endoscopically and histologically diagnosed active duodenal ulcers (33 patients), gastric ulcers (17 patients) or chronic gastritis (71 patients). At the beginning of the study all subjects were H. pyloripositive, as documented by means of gastric mucosa histology (two biopsies from the antrum and two from the body of the stomach) and the rapid urease test (CP test, Yamanouchi) performed on one or two biopsies from the gastric antrum. According to the Sydney system chronic gastritis was defined histologically as the presence of chronic inflammatory cells in the lamina propria, and chronic gastritis activity was graded into four grades : none, mild, moderate and severe, according to the density of neutrophil granulocytes in the lamina propria, in intra-epithelial sites or both."# After diagnosis all patients received a clear explanation of the purpose of the study and those who gave their informed consent were consecutively assigned to one of the following six different regimens, according to a randomization list : (A) omeprazole 20 mg\day for 2-4 weeks plus azithromycin 500 mg\day for 3 days ; (B) Omeprazole, both at 20 and at 40 mg\day, was administered for a period of 4 weeks (in gastric ulcer and duodenal ulcer patients) or 2 weeks (in chronic gastritis patients), and the antibiotics (both in double and triple schedules) were administered during the second week of omeprazole treatment, after histological confirmation of the presence of H. pylori in the gastric mucosa.
Follow-up and serum parameters
In all patients the following procedures were performed at baseline and 2 months after stopping the treatment : upper gastrointestinal endoscopy ; gastric biopsies for histological examination (two from the antrum and two from the gastric body ; H&E plus Giemsa modified stains) and the rapid urease test (CP test, one or two biopsies from the gastric antrum) ; and serum concentrations of IgG anti-H. pylori antibodies using an established enzyme-linked immunosorbent assay (ELISA method ; Biolife, Milan, Italy)."$ The levels of specific anti-H. pylori antibodies were derived from a standard curve of IgG mass against optical density at 450 nm and the results were expressed in monoclonal units\mL (MU\mL) : values beyond a cut-off point of 20 MU\mL were considered as positive ; and serum PGA (RIA method, µg\mL) and PGC (RIA method, µg\mL) levels, and the PGA\PGC ratio.
All patients were clinically evaluated after 2 and 4 weeks to record side-effects and count the tablets : compliance was defined as ' good ' when more than 90 % of the tablets had been taken by the patients. In gastric ulcer and duodenal ulcer patients an intermediate endoscopy (with gastric biopsies) was performed after 4 weeks to evaluate the healing rate of the ulcers.
Statistics
Results were evaluated using both ' per protocol ' and Table 1 shows the epidemiological and clinical characteristics of the patients divided according to the different treatments : no differences were found between the six groups of patients as regards sex, mean age, endoscopic diagnosis and nonsteroidal anti-inflammatory drug (NSAID) use. After 4 weeks of treatment the endoscopy performed in 17 gastric ulcers and 33 duodenal ulcers documented healing of the ulcers in all patients, regardless of the treatment used to cure H. pylori infection. Table 2 shows the H. pylori eradication rates expressed on the basis of per protocol and intention-to-treat analyses. These were less than 50 % with dual therapies (regimens A and D) ; the eradication rates obtained with triple therapies based on omeprazole (at both 20 mg and 40 mg\day) plus metronidazole and azithromycin (regimens B and C) were also not sufficiently effective (less than 65 %). On the other hand, the triple therapies with omeprazole, at 20 or 40 mg\day, plus metronidazole and clarithromycin (regimens E and F) documented eradication rates of over 85 %. Regimens E and F were significantly (P 0.05) more effective than regimens A, B and D. Because no differences as regards the eradication rates were observed between groups B and C (intention-to-treat l 50.0 vs. 65.0 %, P l 0.52 ; per protocol l 55.6 % vs. 76.5 %, P l 0.30) and between groups E and F (intention-to-treat l 85.0 vs. 83.3 %, P l 1.00 ; per protocol l 89.5 vs. 87.0 %, P l 1.00), the patients in groups B and C and in groups E and F were evaluated together : the intention-to-treat and per protocol eradication rates were, respectively, 57.5 and 65.7 % in regimens B and C (omeprazole j metronidazole j azithromycin), and 84.1 and 88.1 % in regimens E and F (omeprazole j metronidazole j clarithromycin). The triple therapy for regimens E and F proved more effective than the dual therapies (intentionto-treat, P 0.007 ; per protocol, P 0.001) or the triple therapy for regimens B and C (intention-to-treat, P 0.009 ; per protocol, P 0.03) (see Table 2 ). Considering all groups we observed six patients (4.9 %) with side-effects (two patients with regimen A, one with regimen B, one with regimen D and two with regimen E) ; however, only three subjects reported major side-effects (one patient with nausea, one with skin rash, and one with metallic taste and oral aphthae) which required suspension of the treatment. Ten patients (8.2 %) dropped out of the study : three owing to side-effects (see above) ; one failed to take the drugs correctly, consuming less than 90 % of the prescribed tablets ; and six patients refused the endoscopic examination 2 months after stopping the treatment. Table 3 illustrates the histological modifications in chronic gastritis activity due to anti-H. pylori therapies : we found a significant improvement in the histological picture, both in patients who became H. pylori-negative after therapy (P 0.001) and in those who remained H. pylori-positive after treatment (P l 0.002) ; however, the histological improvement was much more consistent in the H. pylori-negative group than in the H. pylori-positive group. In fact, while at the beginning of the study there were no differences in gastritis activity between patients who became H. pylori-negative after therapy and patients who were still H. pylori-positive (P l N.S.) 2 months after stopping the therapy, the H. pylori-negative patients presented a significantly better histological situation than the subjects who remained H. pylori-positive (P 0.0001) (see Table 3 ). 
RESULTS
Healing and eradication rate
Gastritis activity
Serum parameters
As illustrated in therapy we found a significant decrease in the anti-H. pylori IgG antibody levels in patients who became H. pylori-negative (104p11.4 vs. 64.4p7.3 MU\mL, P l 0.004), but not in patients who remained H. pyloripositive after treatment (97.1p22.5 vs. 82.0p17.2 MU\mL, P l N. S.). After treatment, seroconversion occurred in 12 of 78 cured patients (15.3 %) and in one of 32 eradicated patients not cured (3.12 %) : the difference was not statistically significant. Figure 2 illustrates the modifications in PGA, PGC and PGA\PGC ratio after treatment : 2 months after therapy a significant decrease in PGC (21.2p1.6 vs. 12.2p1.5 g\mL, P 0.0001) but no change in PGA (148.4p13.7 vs. 137.2p11.9 g\mL, P l N.S.), resulting in a significant increase in the PGA\PGC ratio (7.9p0.5 vs. 10.3p0.4, P 0.001), was found in eradicated patients but not in subjects who remained H. pylori-positive after treatment (PGC, 19.8p2.5 vs. 18.5p2.4 g\mL, P l N. S. ; PGA, 159.6p26.5 vs.
191.6p34.6 g\mL, P l N.S. ; PGA\PGC ratio, 8.37p0.6 vs. 10.85p1.21, P l N.S.).
DISCUSSION
The ' ideal ' therapy for curing H. pylori infection has yet to be established : numerous regimens of treatment have been proposed using two, three and even four drugs concomitantly for different periods."% -"* All of these treatments, however, had never been studied specifically in elderly patients.
In this study we report that azithromycin, plus either omeprazole alone or omeprazole and metronidazole, is not sufficiently effective for the cure of H. pylori in the elderly. Azithromycin is a macrolide with a documented anti-H. pylori activity in vitro and with pharmacokinetic characteristics enabling its clinical use for a brief period (3-7 days for bronchopneumonia infections) and also at low dosages (500-1000 mg\day) with only one administration a day.#! ,#" At present, the only paper published on the use of azithromycin (1000 mg\day for 7 days) in association with omeprazole (40 mg\day for 4 weeks) for the cure of H. pylori infection reported an eradication rate of 90 % ;## other studies have reported varying results.#$ ,#% Our low eradication rates, therefore, may be due to the brief period (3 days) of azithromycin treatment or to the pharmacokinetic characteristics of azithromycin, which is acid-unstable in vitro, presenting a decrease in the anti-H. pylori activity when the pH drops from 7.5 to 5.5 ;#& this may also explain why in our study azithromycin is more effective when associated with metronidazole and omeprazole at the dosage of 40 mg\day than 20 mg\day.
In agreement with other studies performed in nonelderly patients we report that clarithromycin is very effective in the cure of H. pylori in the elderly when associated with nitroimidazole and omeprazole both at 20 and 40 mg\day.#' ,#( The excellent eradication rate obtained with clarithromycin associated with the lower dosage of omeprazole may reflect the high susceptibility of elderly people to the gastric acid inhibitory effect of omeprazole.#) In fact, it has been reported that the optimal dose of omeprazole to inhibit gastric acid secretion in elderly people is 20 mg\day,#* and that in elderly patients with peptic ulcers omeprazole 20 mg\day for 4 weeks is as effective in healing ulcer lesions as omeprazole 40 mg\day.$! In this study side-effects were very rare : only six patients reported side-effects and only three (2.4 %) dropped out as a result of side-effects. It may be that the short duration of the antibiotic therapy (1 week for the clarithromycin regimes) is mainly responsible for this fact. As regards compliance, our data confirm that these medication regimes can be correctly used by elderly patients too : once again, the short duration of the therapy and the adequate explanations may help to ensure valid compliance.
In this study, the eradication of H. pylori from the gastric mucosa induced a dramatic decrease in the activity of chronic gastritis : this is known to occur in the adult population after eradicating H. pylori infection,' ,$" but it remains to be proven in the elderly who, more often than younger patients, present gastric atrophy and\or intestinal metaplasia which are histologically irreversible processes.$# Atrophic gastritis was rare in our population, while a histologically reversible chronic active gastritis was noticed much more frequently.
As regards the modifications induced in serum parameters by the treatment, our study demonstrates that, even after just 2 months of suspending treatment, H. pylori-negative patients showed a significant reduction in IgG anti-H. pylori antibody levels and in PGC, with no changes in PGA, leading to a significant increase in the PGA\PGC ratio. Recently, we reported relatively low values of diagnostic accuracy for all these parameters in elderly people, i.e. 0.60 for anti-H. pylori antibodies, 0.53 for PGA, 0.60 for PGC and 0.68 for PGA\PGC ratio."" However, the fact that there was no change in the IgG anti-H. pylori antibodies or PGA and PGC values in patients whose H. pylori eradication treatment failed supports the conclusion that the study of these serum parameters could provide some clinical information in monitoring H. pylori treatment, especially in elderly patients in whom may it be impossible to perform other tests to verify H. pylori eradication, i.e. the "$C-urea breath test or endoscopy with histological evaluation of gastric biopsies.
In conclusion : triple therapy for 1 week with omeprazole, at 20 or 40 mg\day, plus metronidazole 250 mg q.d.s. and clarithromycin 250 mg b.d., is well tolerated and highly effective as regards both eradication rate and an improvement in chronic gastritis activity ; dual therapies with omeprazole and azithromycin (or clarithromycin) and triple therapy with omeprazole, metronidazole and azithromycin are well tolerated in the elderly but are not effective in the cure of H. pylori infection ; anti-H. pylori antibodies and serum PGC levels decrease soon after anti-H. pylori therapy only in patients cured of H. pylori infection.
